linjc16/ctgov huggingface dataset:
Organoid Model Predictive of Response to Immunotherapies

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to create models out of tissue samples and treat those models with the same immunotherapy treatment the patient will be receiving, in order to validate this process and to predict responses to therapies and use it to choose the best treatments for people in the future. The researchers will then examine the direct effects of the treatment on those models.

Official Title
-----------------
Organoid Model Predictive of Response to Immunotherapies

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Drug: Immunotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥ 18 years old at the time of informed consent Ability to provide written informed consent and HIPAA authorization Biopsy proven diagnosis of cancer Able to obtain at least 2 16 gage cores of fresh tissue safely (3 or more cores preferred) Planning to undergo standard of care Immunotherapy Baseline standard of care CT within 8 weeks of starting Immunotherapy Exclusion Criteria: Inability to provide fresh biopsy sample Any active infections Any conditions that in the opinion of treating physician and the study team will compromise the ability of the patient to receive prescribed treatment to assess the response.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Immunotherapy|Organoid samples will be collected at time of biopsy and cultured in the lab. The samples will then receive the same standard of care immunotherapy treatment as the patient.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Calculate overall patient response rate | Compare patient response using RECIST 1.1 criteria and immune-organoid response based on the following criteria: Complete response <50% of viable tumor cells Response >50%<70% of viable tumor cells Stable >70%<90% viable tumor cell left Progressive >90% of viable tumor cell left | Baseline to 12 months | 
| Reliability of organoid development | calculate the percentage of biopsies with successful organoid development | Baseline to 2 months |
Serum Thyroid Function After Iodinated Contrast Administration

Study Overview
=================
Brief Summary
-----------------
This study investigated the changes in serum thyroid function and urinary iodine levels before and after the use of iodinated contrast to analyze the prevalence of thyroid dysfunction in the Chinese euthyroid adults after using iodinated contrast.

Detailed Description
-----------------
This study aims to monitor the thyroid function, urinary iodine level, and other indicators of patients after using iodine contrast agents, in order to analyze the prevalence of thyroid dysfunction after using iodine containing contrast agents, and investigate the impact of different iodine contrast agents on thyroid function, in order to provide evidence for the use of iodine contrast agents in clinical practice and the risk prevention of subsequent thyroid diseases.

Official Title
-----------------
Serum Thyroid Function After Iodinated Contrast Administration in Chinese Euthyroid Adults: a Prospective Observational Study.

Conditions
-----------------
Thyroid Dysfunction

Intervention / Treatment
-----------------
* Drug: Iodinated contrast agents


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who use iodinated contrast agent Exclusion Criteria: patients with the following diseases: malignant tumor, critical illness (admitted to ICU), mental disease, hypothalamus-pituitary disease. administration of anti-thyroid drugs (methimazole, propylthiouracil), levothyroxine, compound iodine solution, amiodarone, immunostaining point inhibitor, tyrosine kinase inhibitor, interferon, interleukin-6, lithium, glucocorticoids β Receptor blockers, dopamine, dobutamine, bromocriptine, octreotide, phenobarbital, phenytoin sodium, rifampicin, and carbamazepine within the past 6 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Iodinated contrast agents|Patients who use iodinated contrast agents clinically|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence rate of thyroid dysfunction after administration of iodine contrast agent. |  | up to 32 weeks |
A Music-Based Mobile App for People Living With Alzheimer's Disease and Related Dementias (ADRD)

Study Overview
=================
Brief Summary
-----------------
The purpose of this pilot is to develop a mobile application that detects physiological measures of individuals with Alzheimer's disease and related dementias and triggers auto-play of personalized songs in a wearable device. The investigators will test the feasibility and acceptability of the app. This app may be an important tool to include in daily caregiving in a home setting by extending established benefits of music therapy for people with Alzheimer's disease and related dementias.

Official Title
-----------------
A Music-Based Mobile App to Combat Neuropsychiatric Symptoms in People Living With ADRD

Conditions
-----------------
Dementia, Agitation, Depressive Symptoms

Intervention / Treatment
-----------------
* Behavioral: Feasibility study of music-based mobile app


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria for person with dementia A person with ADRD exhibits neuropsychiatric symptoms of dementia such as agitation, restlessness, depressed mood, etc. Stability with or without psychotropic or anti-depressant medications Ability to hear with or without an assistive device Inclusion Criteria for Caregivers Family or close friend caregiver of persons with dementia Must be able to read and write in basic English Exclusion Criteria for all participants Inadequate hearing History of psychosis or other mental disorders other than depression Presence of substance or alcohol abuse
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Feasibility study of music-based mobile app|To determine the performance and usability of the app, 20 dyads will be recruited to test it for 2 weeks. The investigators will collect physiological measures based on the application's demonstration to auto-play music according to movement or sedentary states.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Usability of mobile app | Dyads of caregivers of people with dementia and their caregivers will wear a smartwatch and test the music-based mobile app for two weeks. The person with dementia will wear the smartwatch that will connect to the mobile app for 2 weeks. Caregivers will be asked to complete a daily checklist of their care recipients' behaviors for two weeks. Participants will complete the Usefulness, Satisfaction and Ease of Use questionnaire that describes the usability of the mobile app. The minimum score is 30 while the maximum score is 240. The higher the score means the usability of the app is more acceptable. | 2 weeks |
Living a Pregnancy After a Peri-natal Grief: How Well Does Pregnancy Follow-up Meet Women's Needs and Expectations?

Study Overview
=================
Brief Summary
-----------------
Every year in France, around 7,000 children are born without life, following a medical termination of pregnancy (IMG), fetal death in utero (FDIU) or premature delivery (late miscarriage). For families affected by perinatal bereavement, the pregnancy that follows this silent birth is a moment apart, between anguish and guilt, joy and apprehension. The aim of this research project is to improve the understanding of what women go through during the pregnancy that follows, with a view to proposing a practical tool for the professionals who take care of them, in order to improve and personalize their follow-up.

Official Title
-----------------
Living a Pregnancy After a Peri-natal Grief: How Well Does Pregnancy Follow-up Meet Women's Needs and Expectations?

Conditions
-----------------
Pregnancy Related

Intervention / Treatment
-----------------
* Other: semi structured interview


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women who have given birth to a stillborn child (singleton or twin pregnancies): delivery following fetal death in utero or medical termination of pregnancy at 15 weeks gestational age and later extreme preterm birth (late miscarriage) from 15 weeks gestational age Patient who subsequently carried a pregnancy to term and gave birth to a live, viable child between 2020 and 2023. French-speaking patient Patient who does not object to her participation in this research study Exclusion Criteria: Women who have experienced a natural termination of pregnancy (early miscarriage) before 15 weeks of amenorrhea. Women who have given birth by suction in the operating theatre. Women who are pregnant with twins in the pregnancy following bereavement. Patient under guardianship or curatorship Patient deprived of liberty Patient under court protection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Semi structured interview<br> | Other: semi structured interview<br>* Women fulfilling the inclusion / exclusion criteria will be asked to participate to a semi structured interview with a psychiatrist or a psychologist<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identify women's specific needs and expectations for the follow-up of this particular pregnancy |  | 4months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
peri-natal loss, pregnancy follow up
A Research Registry on Aggressive PitNETs

Study Overview
=================
Brief Summary
-----------------
To allow the identification of markers, it is necessary to extend research networks more widely to collect and properly explore aggressive pituitary tumours. The multidisciplinary consultation meeting (RCP), organised by the reference centre for rare diseases of the pituitary gland, dedicated to aggressive pituitary tumours and carcinomas (HYPOcare), which is unique in France and brings together national experts, currently makes it possible to orientate the management of patients with an aggressive pituitary tumour. With more than 80 patient files discussed since its inception, the patient cohort via the HYPOcare RCP is one of the largest both nationally and internationally. At present, this data source is only dedicated to the clinical management of the files without the possibility of carrying out research work

Official Title
-----------------
A Research Registry on Aggressive PitNETs

Conditions
-----------------
Endocrine Tumor

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria : Patients with a diagnosis of pituitary tumour Patients whose file has been presented to the national HYPOcare RCP Exclusion Criteria : Patients objecting to participating in this research

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients RECAPitNETT<br>All adult subjects with pituitary tumours whose file is presented to the national HYPOcare RCP. There is only one group. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Characterisation of aggressiveness of pituitary tumours by tanscriptome analysis | Molecular and transcriptomic signature of aggressiveness of pituitary tumours predictive of prognosis | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endocrine Tumor, Reference centre, rare diseases, transcriptoms
Analysis of Relevant Influencing Factors of Glycemic Control in Patients With Diabetes

Study Overview
=================
Brief Summary
-----------------
This study aims at the analysis of relevant influencing factors of glycemic control in patients with diabetes.

Official Title
-----------------
Analysis of Relevant Influencing Factors of Glycemic Control in Patients With Diabetes

Conditions
-----------------
Glycemic Control

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged 18-90 years with diabetes and the diagnostic criteria of diabetes is according to the World Health Organization in 1999. Exclusion Criteria: Patients with stress hyperglycaemia. Patients with severe systemic disease. Patients treated with systemic glucocorticoids within the last three months. Patients without any records about HbA1c, CGM and SMBG.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HbA1c | the glycosylated hemoglobin level of patients | day 1 | 
| TIR | time in range observed using continuous glucose monitoring | day 1-14 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MBG | mean blood glucose | day 1-14 | 
| MAGE | Mean amplitude of glycemic excursion assessed by continuous glucose monitoring | day 1-14 | 
| SD | the standard deviation of mean glucose | day 1-14 | 
| Incidence of hypoglycemia | Incidence of hypoglycemia | day 1-14 |
Phamacokinetics and Safety Profiles of DA-1229_01 2.5/500mg in Healthy Subjects at Fed State

Study Overview
=================
Brief Summary
-----------------
This Phase I clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229_01(2.5/500 mg x1 tablets) at fed state

Official Title
-----------------
An Open Label, Randomized, Single Dose, Cross-over ,Two-group Study to Evaluate the Pharmacokinetics and Safety of DA-1229_01 2.5/500mg in Healthy Subjects at Fed State

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: DA-1229_01 2.5/500mg (Before)
* Drug: DA-1229_01 2.5/500mg (After)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy Volunteers BMI between 18 and 30 kg/m2 Body weight : Male≥50kg, Female≥45kg Exclusion Criteria: Allergy or Drug hypersensitivity Clinically significant Medical History

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sequence A(Before→ After)<br> | Drug: DA-1229_01 2.5/500mg (Before)<br>* single dose administration (one tablet once a day)<br>Drug: DA-1229_01 2.5/500mg (After)<br>* single dose administration (one tablet once a day)<br>|
| Experimental: Sequence B(After→ Before)<br> | Drug: DA-1229_01 2.5/500mg (Before)<br>* single dose administration (one tablet once a day)<br>Drug: DA-1229_01 2.5/500mg (After)<br>* single dose administration (one tablet once a day)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUCt | area under the curve | pre-dose 48 hours post-dose | 
| Cmax | maximum plasma concentration | pre-dose 48 hours post-dose |
Alio WEAR Study: Long-term Wear of the Alio Platform

Study Overview
=================
Brief Summary
-----------------
The WEAR study is long-term interventional study designed to evaluate patient and clinician use of the Alio platform, per its FDA cleared indications.

Official Title
-----------------
Alio WEAR Study: Long-term Wear of the Alio Platform

Conditions
-----------------
End Stage Kidney Disease

Intervention / Treatment
-----------------
* Device: Alio platform


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 18 years of age. Receiving hemodialysis via an AVF or AVG in an arm location at the time of study start. Able to wear the SmartPatch effectively at the specified location on the arm. Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures. Willing and able to wear the SmartPatch as instructed and comply with all interviews, surveys and questionnaires, and schedule of evaluations. Exclusion Criteria: Skin near the proximity of the AV access that is chronically swollen, infected, inflamed, open wounds, lesions, or has skin eruptions. Participation in any other clinical trials involving investigational or marketed products that in the opinion of the investigator could affect the quality of the data. Other conditions that in the opinion of the Principal Investigator may increase risk to the subject and/or compromise the quality of the clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Test Subject<br>All subjects who are enrolled into the test group and participate in data collection receive the noninvasive Alio platform. | Device: Alio platform<br>* Remote monitoring platform<br>|
| No Intervention: Control Subject<br>All subjects who are enrolled into the control group and participate in data collection will not receive the noninvasive Alio platform. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessing usage of the Alio platform by the test subject | Assessing compliance and ease of use via surveys | Up to 1 year |
Photogrammetric Scan System for Body Composition Analysis

Study Overview
=================
Brief Summary
-----------------
This observational study evaluates the goodness of the IGOODI photogrammetric scan system in measuring anthropometry and estimating the body composition of 75 healthy subjects, comparing the results with the measurements taken using methods used in clinical practice, including body circumferences and bioimpedance analysis.

Official Title
-----------------
The Use of Photogrammetric Technology for the Evaluation of Anthropometric Measurements and Body Composition

Conditions
-----------------
Anthropometry, Musculoskeletal System

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female gender Between the ages of 18 and 85 Caucasian race Cognitively intact Acceptance and signing of informed consent Height between 120 and 200 cm (included) Exclusion Criteria: Congenital or acquired musculoskeletal deformities of the limbs or trunk Implants resulting from cosmetic surgery Articular prostheses and/or means of synthesis Current oncological or metabolic pathologies Photosensitivity Epilepsy Claustrophobia Subjects unable to independently maintain an upright position Wearers of pacemakers

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between anthropometric circumferences | Association between the circumferences taken with clinical practice methodology (inelastic and flexible tape measure) and the results from the photogrammetric technology | Baseline and after 1 year |